Computed Tomography with Contrast

PROCEDURE7 trials

Sponsors

National Cancer Institute (NCI), M.D. Anderson Cancer Center, Mayo Clinic

Conditions

Advanced Adrenal Gland PheochromocytomaAdvanced Lung Non-Small Cell CarcinomaAdvanced ParagangliomaFallopian Tube Mucinous AdenocarcinomaHereditary Leiomyomatosis and Renal Cell CarcinomaLocally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma

Phase 2

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

RecruitingNCT03191149

National Cancer Institute (NCI)Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7 +1

Start: 2018-04-25End: 2027-06-30Target: 46Updated: 2026-04-03

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Active, not recruitingNCT03237780

National Cancer Institute (NCI)Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma +21

Start: 2018-07-20End: 2027-06-30Target: 72Updated: 2026-04-03

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

Active, not recruitingNCT04394858

National Cancer Institute (NCI)Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma +5

Start: 2021-03-17End: 2028-03-01Target: 46Updated: 2026-04-03

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Active, not recruitingNCT04739800

National Cancer Institute (NCI)Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma +47

Start: 2021-06-10End: 2026-11-25Updated: 2026-03-05

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

RecruitingNCT04981509

National Cancer Institute (NCI)Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma +3

Start: 2022-06-10End: 2027-12-31Target: 65Updated: 2026-04-03

Unknown Phase

Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study

Active, not recruitingNCT04430725

M.D. Anderson Cancer CenterLung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Sarcoma +19

Start: 2019-08-07End: 2026-01-01Updated: 2025-10-22

A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer

RecruitingNCT07324096

Mayo ClinicPancreatic Ductal Adenocarcinoma

Start: 2026-03-24End: 2029-03-24Target: 100Updated: 2026-03-27

Related Papers

Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.

Journal of Clinical Oncology2023-06-014 citations

A phase 2 study of bevacizumab, erlotinib, and atezolizumab in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) associated or sporadic papillary renal cell cancer (pRCC).

Journal of Clinical Oncology2022-06-012 citations

Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)

Clinical Lung Cancer2021-05-1516 citations

ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.

Journal of Clinical Oncology2020-05-20103 citations